Recently, sodium-glucose cotransporter-2 inhibitors (SGLT2is) and certain glucagon-like peptide 1 receptor agonists (GLP-1RAs) were recommended as first-line treatments, along with MET, in CKD patients due to their nephroprotective and cardiovascular benefits. Here, GLP1R is linked to chronic kidney disease.